Navigation Links
Roche Receives FDA Approval for cobas p 630 Pre-analytical Solution for Automated Molecular Testing Platform
Date:3/30/2012

PLEASANTON, Calif., March 30, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the FDA approval of a new pre-analytical instrument that provides an integrated primary tube handling solution for its widely adopted automated molecular testing platform. The cobas p 630 Instrument, being introduced with new AMPLILINK 3.3 series software, unites primary tube handling with fully automated sample preparation, amplification and detection for molecular diagnostics on COBAS® AmpliPrep instruments and COBAS® TaqMan® analyzers.

"The complete system provides molecular laboratories with a flexible and integrated solution for automated pre-analytics and real-time PCR diagnostic testing," said Paul Brown, Ph.D., Head of Roche Molecular Diagnostics. "Combined with the latest version of our software, the cobas p 630 Instrument helps labs enhance their throughput for a broad menu of important molecular virology tests, including HIV, hepatitis B and hepatitis C."

The cobas p 630 Instrument is designed to protect the integrity of the primary patient tube and combines automated primary tube handling with full sample traceability, process surveillance and bi-directional connectivity. Together, these features help labs improve efficiency by effectively eliminating manual steps.

The cobas p 630 Instrument has a number of additional automation features that ensure full sample traceability while reducing hands-on labor time. The cobas p 630 Instrument received CE mark in October 2009 and is used throughout Europe, Africa, Asia and South America.

About AMPLILINK 3.3 series software
AMPLILINK Software, a Windows® operating system-based application, is designed to deliver maximum flexibility, efficiency and integrity to the laboratory's workflow – from sample input through results output. AMPLILINK 3.3 series software is an intuitive graphical user interface that manages the operation of the connected CO
'/>"/>

SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rochester Medical Reports Fiscal 2012 First Quarter Results
2. Roches Sequence Capture Technology Used to Identify SMPX Mutations Underlying Human Hereditary Hearing Loss
3. Rochester Medical Announces First Quarter 2012 Earnings Conference Call, Wednesday, January 25, 2012
4. Rochester Medical Director Schnobrich to Retire
5. Roche Acquires Verum Diagnostica GmbH as Part of Plan to Develop Comprehensive Coagulation Testing Portfolio for Diagnostic Laboratories
6. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
7. Roche Diagnostics, Cedars-Sinai Medical Center Enter Strategic Alliance for Center to Operate as a Roche Molecular Center of Excellence
8. Rochester Medical Reports Fourth Quarter and Fiscal Year End Results
9. Roche Receives FDA Approval for Acute Hepatitis B Test
10. Rochester Medical Announces Fourth Quarter 2011 Earnings Conference Call Thursday, November 3, 2011
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 Richmond Pharmacology is ... with a worldwide reputation for excellence in clinical ... in peer reviewed medical journals. Its officers are ... in discussions about rules for transparency and publication ... http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is conducted ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group ... antibody asset currently under development by GSK in the field of oncology. ... "ImaginAb is pleased to ... Behrenbruch , CEO of ImaginAb. "Not only does GSK have an excellent ...
... , SOUTH SAN FRANCISCO, Calif. , May ... from 32 prospective studies was published in The ... data shows that elevated levels of lipoprotein-associated phospholipase A2 ... increased risk of coronary heart disease similar in magnitude ...
Cached Medicine Technology:ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... targeted therapies can reduce tumors rapidly. However, not all ... do often develop resistance over time. Looking for a ... Fox Chase Cancer Center hypothesized that hitting already weakened ... thembut only if it was the right second agent. ...
... be improved with training and the improvement is marked ... University study. A research team led by ... of the brain that controls impulsive behavior and the ... findings could have a significant impact on the diagnosis ...
... By Steven Reinberg HealthDay Reporter , ... finds it,s safe to take the blood thinner Plavix ... that said the combination compromised Plavix,s effectiveness. "We ... and proton-pump inhibitors," said lead researcher Dr. Mette Charlot ...
... tenth anniversary of the Jackson Heart Study (JHS) will ... JHS is the largest study in history to investigate ... lung disease, stroke, diabetes, and other important diseases in ... among African-Americans than among whites in the United States. ...
... CHAPEL HILL, N.C. Scientists from University of North Carolina ... Inc. announced today findings from a large clinical study ... the worsening of osteoarthritis. The study, which was ... with X-ray evidence of knee osteoarthritis who inherited a ...
Cached Medicine News:Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 3Health News:Queen's University researchers locate impulse control center in brain 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:NIH celebrates 10 years of research into health disparities 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 3
... respiration and ventilation., ,The Capnomac Ultima is ... monitors available. The Capnomac Ultima is available in ... measure the essential airway gas parameters, CO 2 ... O easily and reliability. The Capnomac Ultima also ...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds as well as for gastric suctioning....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: